<?xml version="1.0" encoding="UTF-8"?>
<table-wrap id="table4-1759720X20947296" orientation="portrait" position="float">
 <label>Table 4.</label>
 <caption>
  <p>Clinical studies regarding antiviral activities of DMARDs and immunosuppressants.</p>
 </caption>
 <alternatives>
  <graphic xlink:href="10.1177_1759720X20947296-table4" xmlns:xlink="http://www.w3.org/1999/xlink"/>
  <table frame="hsides" rules="groups">
   <colgroup span="1">
    <col align="left" span="1"/>
    <col align="char" char="." span="1"/>
    <col align="char" char="." span="1"/>
    <col align="char" char="." span="1"/>
    <col align="char" char="." span="1"/>
   </colgroup>
   <thead>
    <tr>
     <th align="left" rowspan="1" colspan="1">Medications</th>
     <th align="left" rowspan="1" colspan="1">Viral susceptibility</th>
     <th align="left" rowspan="1" colspan="1">
      <italic>In vitro</italic>
     </th>
     <th align="left" rowspan="1" colspan="1">Animal study</th>
     <th align="left" rowspan="1" colspan="1">Clinical report</th>
    </tr>
   </thead>
   <tbody>
    <tr>
     <td rowspan="1" colspan="1">
      <bold>Chloroquine</bold>
      <break/>
      <bold>HCQ</bold>
     </td>
     <td rowspan="1" colspan="1">SARS-CoV</td>
     <td rowspan="1" colspan="1">Freund 
      <italic>et al</italic>.,
      <sup>
       <xref rid="bibr30-1759720X20947296" ref-type="bibr">30</xref>
      </sup> Keyaerts 
      <italic>et al</italic>.,
      <sup>
       <xref rid="bibr31-1759720X20947296" ref-type="bibr">31</xref>
      </sup> Vincent 
      <italic>et al</italic>.
      <sup>
       <xref rid="bibr32-1759720X20947296" ref-type="bibr">32</xref>
      </sup>
     </td>
     <td rowspan="1" colspan="1"/>
     <td rowspan="1" colspan="1"/>
    </tr>
    <tr>
     <td rowspan="1" colspan="1"/>
     <td rowspan="1" colspan="1">HIV</td>
     <td rowspan="1" colspan="1">✓ Savarino 
      <italic>et al</italic>.,
      <sup>
       <xref rid="bibr33-1759720X20947296" ref-type="bibr">33</xref>
      </sup> Boelaert et al.
      <sup>
       <xref rid="bibr34-1759720X20947296" ref-type="bibr">34</xref>
      </sup>
     </td>
     <td rowspan="1" colspan="1"/>
     <td rowspan="1" colspan="1">✓ RCT (
      <italic>n</italic> = 40): moderate efficacy
      <sup>
       <xref rid="bibr35-1759720X20947296" ref-type="bibr">35</xref>
      </sup>
      <break/>✓ Cohort (
      <italic>n</italic> = 287): decreased HIV vertical transmission
      <sup>
       <xref rid="bibr36-1759720X20947296" ref-type="bibr">36</xref>
      </sup>
      <break/>✓ RCT (
      <italic>n</italic> = 12): reduced T-cell immune activation; no effect on viral load
      <sup>
       <xref rid="bibr37-1759720X20947296" ref-type="bibr">37</xref>
      </sup>
      <break/>✓ Prospective (
      <italic>n</italic> = 20): significant reduction immune activation
      <sup>
       <xref rid="bibr38-1759720X20947296" ref-type="bibr">38</xref>
      </sup>
      <break/>✗ RCT (
      <italic>n</italic> = 83): no efficacy
      <sup>
       <xref rid="bibr39-1759720X20947296" ref-type="bibr">39</xref>
      </sup>
      <break/>✗ Single-arm, pilot (
      <italic>n</italic> = 20): not beneficial
      <sup>
       <xref rid="bibr40-1759720X20947296" ref-type="bibr">40</xref>
      </sup>
     </td>
    </tr>
    <tr>
     <td rowspan="1" colspan="1"/>
     <td rowspan="1" colspan="1">Dengue virus</td>
     <td rowspan="1" colspan="1">✓ Farias 
      <italic>et al</italic>.
      <sup>
       <xref rid="bibr41-1759720X20947296" ref-type="bibr">41</xref>
      </sup>
     </td>
     <td rowspan="1" colspan="1">✓ Farias 
      <italic>et al</italic>.
      <sup>
       <xref rid="bibr42-1759720X20947296" ref-type="bibr">42</xref>
      </sup>
     </td>
     <td rowspan="1" colspan="1">✓ RCT (
      <italic>n</italic> = 37): improve dengue-related symptoms
      <sup>
       <xref rid="bibr43-1759720X20947296" ref-type="bibr">43</xref>
      </sup>
      <break/>✗ RCT (
      <italic>n</italic> = 307): reduced fever period; no efficacy
      <sup>
       <xref rid="bibr44-1759720X20947296" ref-type="bibr">44</xref>
      </sup>
     </td>
    </tr>
    <tr>
     <td rowspan="1" colspan="1"/>
     <td rowspan="1" colspan="1">Chikungunya virus</td>
     <td rowspan="1" colspan="1">✓ Kaur and Chu
      <sup>
       <xref rid="bibr45-1759720X20947296" ref-type="bibr">45</xref>
      </sup>
     </td>
     <td rowspan="1" colspan="1"/>
     <td rowspan="1" colspan="1">✓ Open pilot study (
      <italic>n</italic> = 10): 50% improved clinically
      <sup>
       <xref rid="bibr46-1759720X20947296" ref-type="bibr">46</xref>
      </sup>
      <break/>✗ RCT (
      <italic>n</italic> = 54): no significant decrease in viremia
      <sup>
       <xref rid="bibr47-1759720X20947296" ref-type="bibr">47</xref>
      </sup>
     </td>
    </tr>
    <tr>
     <td rowspan="1" colspan="1"/>
     <td rowspan="1" colspan="1">Influenza A virus</td>
     <td rowspan="1" colspan="1">✓ Fedson
      <sup>
       <xref rid="bibr48-1759720X20947296" ref-type="bibr">48</xref>
      </sup>
     </td>
     <td rowspan="1" colspan="1">✓ Yan 
      <italic>et al</italic>.
      <sup>
       <xref rid="bibr49-1759720X20947296" ref-type="bibr">49</xref>
      </sup>
     </td>
     <td rowspan="1" colspan="1">✓ Prospective study (
      <italic>n</italic> = 555): beneficial
      <sup>
       <xref rid="bibr50-1759720X20947296" ref-type="bibr">50</xref>
      </sup>
      <break/>✗ RCT (
      <italic>n</italic> = 1496): no preventive effect
      <sup>
       <xref rid="bibr51-1759720X20947296" ref-type="bibr">51</xref>
      </sup>
     </td>
    </tr>
    <tr>
     <td rowspan="1" colspan="1"/>
     <td rowspan="1" colspan="1">HCV</td>
     <td rowspan="1" colspan="1">✓ Ashfaq 
      <italic>et al</italic>.
      <sup>
       <xref rid="bibr52-1759720X20947296" ref-type="bibr">52</xref>
      </sup>
     </td>
     <td rowspan="1" colspan="1"/>
     <td rowspan="1" colspan="1">✓ 
      <italic>n</italic> = 1: 42 years, male with liver transplantation; PCT improved
      <sup>
       <xref rid="bibr53-1759720X20947296" ref-type="bibr">53</xref>
      </sup>
     </td>
    </tr>
    <tr>
     <td rowspan="1" colspan="1"/>
     <td rowspan="1" colspan="1">Zika virus</td>
     <td rowspan="1" colspan="1">✓ Li 
      <italic>et al</italic>.
      <sup>
       <xref rid="bibr54-1759720X20947296" ref-type="bibr">54</xref>
      </sup>
     </td>
     <td rowspan="1" colspan="1">✓ Li 
      <italic>et al</italic>.
      <sup>
       <xref rid="bibr54-1759720X20947296" ref-type="bibr">54</xref>
      </sup>
     </td>
     <td rowspan="1" colspan="1"/>
    </tr>
    <tr>
     <td rowspan="1" colspan="1">
      <bold>Cyclosporine A</bold>
     </td>
     <td rowspan="1" colspan="1">HIV</td>
     <td rowspan="1" colspan="1">✓ Thali 
      <italic>et al</italic>.
      <sup>
       <xref rid="bibr55-1759720X20947296" ref-type="bibr">55</xref>
      </sup>
     </td>
     <td rowspan="1" colspan="1"/>
     <td rowspan="1" colspan="1">✓ Retrospective study (
      <italic>n</italic> = 27): effective
      <sup>
       <xref rid="bibr56-1759720X20947296" ref-type="bibr">56</xref>
      </sup>
      <break/>✗ RCT (
      <italic>n</italic> = 28): no benefits under low-dose CsA
      <sup>
       <xref rid="bibr57-1759720X20947296" ref-type="bibr">57</xref>
      </sup>
     </td>
    </tr>
    <tr>
     <td rowspan="1" colspan="1"/>
     <td rowspan="1" colspan="1">HCV genotype 1</td>
     <td rowspan="1" colspan="1">✓ Liu 
      <italic>et al</italic>.,
      <sup>
       <xref rid="bibr58-1759720X20947296" ref-type="bibr">58</xref>
      </sup> Watashi 
      <italic>et al</italic>.
      <sup>
       <xref rid="bibr59-1759720X20947296" ref-type="bibr">59</xref>
      </sup>
     </td>
     <td rowspan="1" colspan="1"/>
     <td rowspan="1" colspan="1">✓ Placebo-controlled trial (
      <italic>n</italic> = 120): increased sustained virological response
      <sup>
       <xref rid="bibr60-1759720X20947296" ref-type="bibr">60</xref>
      </sup>
     </td>
    </tr>
    <tr>
     <td rowspan="1" colspan="1"/>
     <td rowspan="1" colspan="1">Flavivirus (Zika virus, Dengue virus, West Nile virus, Yellow fever virus)</td>
     <td rowspan="1" colspan="1">✓ Qing 
      <italic>et al</italic>.,
      <sup>
       <xref rid="bibr61-1759720X20947296" ref-type="bibr">61</xref>
      </sup> Barrows 
      <italic>et al</italic>.
      <sup>
       <xref rid="bibr62-1759720X20947296" ref-type="bibr">62</xref>
      </sup>
     </td>
     <td rowspan="1" colspan="1"/>
     <td rowspan="1" colspan="1"/>
    </tr>
    <tr>
     <td rowspan="1" colspan="1"/>
     <td rowspan="1" colspan="1">Betaretrovirus</td>
     <td rowspan="1" colspan="1">✓ Montano-Loza 
      <italic>et al</italic>.
      <sup>
       <xref rid="bibr63-1759720X20947296" ref-type="bibr">63</xref>
      </sup>
     </td>
     <td rowspan="1" colspan="1"/>
     <td rowspan="1" colspan="1"/>
    </tr>
    <tr>
     <td rowspan="1" colspan="1">
      <bold>Hydroxyurea</bold>
     </td>
     <td rowspan="1" colspan="1">HIV</td>
     <td rowspan="1" colspan="1">✓ Lori and Lisziewicz
      <sup>
       <xref rid="bibr64-1759720X20947296" ref-type="bibr">64</xref>
      </sup>
     </td>
     <td rowspan="1" colspan="1"/>
     <td rowspan="1" colspan="1">✓ RCT (
      <italic>n</italic> = 57): greater decrease in viral load
      <sup>
       <xref rid="bibr65-1759720X20947296" ref-type="bibr">65</xref>
      </sup>
      <break/>✓ RCT (
      <italic>n</italic> = 144): greater decrease of HIV RNA levels
      <sup>
       <xref rid="bibr66-1759720X20947296" ref-type="bibr">66</xref>
      </sup>
      <break/>✓ RCT (
      <italic>n</italic> = 69): higher rate reached HIV RNA level &lt;200 and &lt;20
      <sup>67</sup>
      <break/>✓ RCT (
      <italic>n</italic> = 134): greater decrease of HIV RNA levels
      <sup>
       <xref rid="bibr68-1759720X20947296" ref-type="bibr">68</xref>
      </sup>
      <break/>✓ RCT (
      <italic>n</italic> = 21): HIV RNA significant decrease, but no added benefit compared with placebo active comparator
      <sup>
       <xref rid="bibr69-1759720X20947296" ref-type="bibr">69</xref>
      </sup>
     </td>
    </tr>
    <tr>
     <td rowspan="1" colspan="1"/>
     <td rowspan="1" colspan="1">HCV</td>
     <td rowspan="1" colspan="1">✓ Nozaki 
      <italic>et al</italic>.
      <sup>
       <xref rid="bibr70-1759720X20947296" ref-type="bibr">70</xref>
      </sup>
     </td>
     <td rowspan="1" colspan="1"/>
     <td rowspan="1" colspan="1">✓ phase I (
      <italic>n</italic> = 9): 8 people achieved moderate decrease in serum HCV RNA levels
      <sup>
       <xref rid="bibr71-1759720X20947296" ref-type="bibr">71</xref>
      </sup>
     </td>
    </tr>
    <tr>
     <td rowspan="1" colspan="1"/>
     <td rowspan="1" colspan="1">HBV</td>
     <td rowspan="1" colspan="1"/>
     <td rowspan="1" colspan="1"/>
     <td rowspan="1" colspan="1">✓ 
      <italic>n</italic> = 4: significant decrease of viral loads in all patients
      <sup>
       <xref rid="bibr72-1759720X20947296" ref-type="bibr">72</xref>
      </sup>
      <break/>✗ 
      <italic>n</italic> = 1, HBV reactivation
      <sup>
       <xref rid="bibr73-1759720X20947296" ref-type="bibr">73</xref>
      </sup>
     </td>
    </tr>
    <tr>
     <td rowspan="1" colspan="1"/>
     <td rowspan="1" colspan="1">HSV</td>
     <td rowspan="1" colspan="1">✓ Rosenkranz and Becker,
      <sup>
       <xref rid="bibr74-1759720X20947296" ref-type="bibr">74</xref>
      </sup> Sergerie and Boivin
      <sup>
       <xref rid="bibr75-1759720X20947296" ref-type="bibr">75</xref>
      </sup>
     </td>
     <td rowspan="1" colspan="1"/>
     <td rowspan="1" colspan="1"/>
    </tr>
    <tr>
     <td rowspan="1" colspan="1"/>
     <td rowspan="1" colspan="1">Parvovirus B19</td>
     <td rowspan="1" colspan="1">✓ Bonvicini 
      <italic>et al</italic>.
      <sup>
       <xref rid="bibr76-1759720X20947296" ref-type="bibr">76</xref>
      </sup>
     </td>
     <td rowspan="1" colspan="1"/>
     <td rowspan="1" colspan="1">✓ Retrospective review (
      <italic>n</italic> = 120): require fewer transfusions; higher nadir Hb concentration
      <sup>
       <xref rid="bibr77-1759720X20947296" ref-type="bibr">77</xref>
      </sup>
     </td>
    </tr>
    <tr>
     <td rowspan="1" colspan="1">
      <bold>Minocycline</bold>
     </td>
     <td rowspan="1" colspan="1">HIV</td>
     <td rowspan="1" colspan="1">✓ Si 
      <italic>et al</italic>.
      <sup>
       <xref rid="bibr78-1759720X20947296" ref-type="bibr">78</xref>
      </sup>
     </td>
     <td rowspan="1" colspan="1">✓ Less degeneration of axons and less CNS replication of virus 
      <sup>79</sup>
     </td>
     <td rowspan="1" colspan="1">✗ RCT (
      <italic>n</italic> = 107): no difference in cognitive function
      <sup>
       <xref rid="bibr80-1759720X20947296" ref-type="bibr">80</xref>
      </sup>
      <break/>✗ RCT (
      <italic>n</italic> = 73): no difference in cognitive function
      <sup>
       <xref rid="bibr81-1759720X20947296" ref-type="bibr">81</xref>
      </sup>
     </td>
    </tr>
    <tr>
     <td rowspan="1" colspan="1"/>
     <td rowspan="1" colspan="1">Japanese encephalitis virus</td>
     <td rowspan="1" colspan="1">✓ Mishra and Basu
      <sup>
       <xref rid="bibr82-1759720X20947296" ref-type="bibr">82</xref>
      </sup>
     </td>
     <td rowspan="1" colspan="1">✓ Reduce viral titers, neuronal apoptosis
      <sup>
       <xref rid="bibr83-1759720X20947296" ref-type="bibr">83</xref>
      </sup>
     </td>
     <td rowspan="1" colspan="1">✓ RCT (
      <italic>n</italic> = 44), 1–13 years: duration of fever, unconsciousness, and hospital stay significantly reduced; mortality rate unchanged
      <sup>
       <xref rid="bibr84-1759720X20947296" ref-type="bibr">84</xref>
      </sup>
      <break/>✓ RCT (
      <italic>n</italic> = 281): a trend towards better outcomes
      <sup>
       <xref rid="bibr85-1759720X20947296" ref-type="bibr">85</xref>
      </sup>
     </td>
    </tr>
    <tr>
     <td rowspan="1" colspan="1"/>
     <td rowspan="1" colspan="1">Dengue virus</td>
     <td rowspan="1" colspan="1">✓ Leela 
      <italic>et al</italic>.
      <sup>
       <xref rid="bibr86-1759720X20947296" ref-type="bibr">86</xref>
      </sup>
     </td>
     <td rowspan="1" colspan="1"/>
     <td rowspan="1" colspan="1"/>
    </tr>
    <tr>
     <td rowspan="1" colspan="1"/>
     <td rowspan="1" colspan="1">RSV</td>
     <td rowspan="1" colspan="1">✓ Bawage 
      <italic>et al</italic>.
      <sup>
       <xref rid="bibr87-1759720X20947296" ref-type="bibr">87</xref>
      </sup>
     </td>
     <td rowspan="1" colspan="1"/>
     <td rowspan="1" colspan="1"/>
    </tr>
    <tr>
     <td rowspan="1" colspan="1"/>
     <td rowspan="1" colspan="1">Enterovirus 71</td>
     <td rowspan="1" colspan="1">✓ Liao 
      <italic>et al</italic>.
      <sup>
       <xref rid="bibr88-1759720X20947296" ref-type="bibr">88</xref>
      </sup>
     </td>
     <td rowspan="1" colspan="1">✓ Decrease mortality rates, clinical scores, viral titers
      <sup>
       <xref rid="bibr68-1759720X20947296" ref-type="bibr">68</xref>
      </sup>
     </td>
     <td rowspan="1" colspan="1"/>
    </tr>
    <tr>
     <td rowspan="1" colspan="1"/>
     <td rowspan="1" colspan="1">Influenza virus</td>
     <td rowspan="1" colspan="1">✓ Josset 
      <italic>et al</italic>.
      <sup>
       <xref rid="bibr89-1759720X20947296" ref-type="bibr">89</xref>
      </sup>
     </td>
     <td rowspan="1" colspan="1"/>
     <td rowspan="1" colspan="1"/>
    </tr>
    <tr>
     <td rowspan="1" colspan="1"/>
     <td rowspan="1" colspan="1">West Nile virus</td>
     <td rowspan="1" colspan="1">✓ Michaelis 
      <italic>et al</italic>.
      <sup>
       <xref rid="bibr90-1759720X20947296" ref-type="bibr">90</xref>
      </sup>
     </td>
     <td rowspan="1" colspan="1"/>
     <td rowspan="1" colspan="1"/>
    </tr>
    <tr>
     <td rowspan="1" colspan="1"/>
     <td rowspan="1" colspan="1">Reovirus</td>
     <td rowspan="1" colspan="1"/>
     <td rowspan="1" colspan="1">✓ Delay encephalitis onset; reduce mortality
      <sup>
       <xref rid="bibr91-1759720X20947296" ref-type="bibr">91</xref>
      </sup>
     </td>
     <td rowspan="1" colspan="1"/>
    </tr>
    <tr>
     <td rowspan="1" colspan="1"/>
     <td rowspan="1" colspan="1">Rabies</td>
     <td rowspan="1" colspan="1"/>
     <td rowspan="1" colspan="1">✗ Worse, higher mortality rate
      <sup>
       <xref rid="bibr92-1759720X20947296" ref-type="bibr">92</xref>
      </sup>
     </td>
     <td rowspan="1" colspan="1"/>
    </tr>
    <tr>
     <td rowspan="1" colspan="1">
      <bold>Mycophenolate mofetil/Mycophenolic acid</bold>
     </td>
     <td rowspan="1" colspan="1">HIV</td>
     <td rowspan="1" colspan="1">✓ Chapuis 
      <italic>et al</italic>.
      <sup>
       <xref rid="bibr93-1759720X20947296" ref-type="bibr">93</xref>
      </sup>
     </td>
     <td rowspan="1" colspan="1">✓ Inhibition of virus isolation from purified CD4+ T-cell populations.
      <sup>
       <xref rid="bibr93-1759720X20947296" ref-type="bibr">93</xref>
      </sup>
     </td>
     <td rowspan="1" colspan="1">✓ RCT (
      <italic>n</italic> = 17): combine MMF and HAART delayed viral load rebound and improved control of viral replication
      <sup>
       <xref rid="bibr26-1759720X20947296" ref-type="bibr">26</xref>
      </sup>
     </td>
    </tr>
    <tr>
     <td rowspan="1" colspan="1"/>
     <td rowspan="1" colspan="1">Influenza virus</td>
     <td rowspan="1" colspan="1">✓ To 
      <italic>et al</italic>.
      <sup>
       <xref rid="bibr27-1759720X20947296" ref-type="bibr">27</xref>
      </sup>
     </td>
     <td rowspan="1" colspan="1">✓ All mice survived; viral titers in lungs markedly reduced
      <sup>
       <xref rid="bibr94-1759720X20947296" ref-type="bibr">94</xref>
      </sup>
     </td>
     <td rowspan="1" colspan="1"/>
    </tr>
    <tr>
     <td rowspan="1" colspan="1"/>
     <td rowspan="1" colspan="1">MERS-CoV</td>
     <td rowspan="1" colspan="1">✓ Chan 
      <italic>et al</italic>.
      <sup>
       <xref rid="bibr95-1759720X20947296" ref-type="bibr">95</xref>
      </sup>
     </td>
     <td rowspan="1" colspan="1">✗ Severe and fatal disease; higher viral loads than the untreated animals
      <sup>
       <xref rid="bibr96-1759720X20947296" ref-type="bibr">96</xref>
      </sup>
     </td>
     <td rowspan="1" colspan="1"/>
    </tr>
    <tr>
     <td rowspan="1" colspan="1">
      <bold>Leflunomide</bold>
     </td>
     <td rowspan="1" colspan="1">HSV</td>
     <td rowspan="1" colspan="1">✓ Knight 
      <italic>et al</italic>.
      <sup>
       <xref rid="bibr97-1759720X20947296" ref-type="bibr">97</xref>
      </sup>
     </td>
     <td rowspan="1" colspan="1"/>
     <td rowspan="1" colspan="1">✓ 
      <italic>n</italic> = 1: 42 years, male with HIV
      <sup>
       <xref rid="bibr98-1759720X20947296" ref-type="bibr">98</xref>
      </sup>
      <break/>✓ 
      <italic>n</italic> = 1: 52 years, male with HIV
      <sup>
       <xref rid="bibr99-1759720X20947296" ref-type="bibr">99</xref>
      </sup>
     </td>
    </tr>
    <tr>
     <td rowspan="1" colspan="1"/>
     <td rowspan="1" colspan="1">HIV</td>
     <td rowspan="1" colspan="1">✓ Hossain and Margolis,
      <sup>
       <xref rid="bibr100-1759720X20947296" ref-type="bibr">100</xref>
      </sup> Schlapfer 
      <italic>et al</italic>.
      <sup>
       <xref rid="bibr101-1759720X20947296" ref-type="bibr">101</xref>
      </sup>
     </td>
     <td rowspan="1" colspan="1"/>
     <td rowspan="1" colspan="1">✓ RCT (
      <italic>n</italic> = 18): stable CD4+ T-cell counts
      <sup>
       <xref rid="bibr102-1759720X20947296" ref-type="bibr">102</xref>
      </sup>
     </td>
    </tr>
    <tr>
     <td rowspan="1" colspan="1"/>
     <td rowspan="1" colspan="1">Molluscum and verruca</td>
     <td rowspan="1" colspan="1"/>
     <td rowspan="1" colspan="1"/>
     <td rowspan="1" colspan="1">✓ 
      <italic>n</italic> = 3 with AD
      <sup>
       <xref rid="bibr103-1759720X20947296" ref-type="bibr">103</xref>
      </sup>
      <break/>✓ 
      <italic>n</italic> = 3 with renal transplantation
      <sup>
       <xref rid="bibr104-1759720X20947296" ref-type="bibr">104</xref>
      </sup>
     </td>
    </tr>
    <tr>
     <td rowspan="1" colspan="1"/>
     <td rowspan="1" colspan="1">CMV</td>
     <td rowspan="1" colspan="1">✓ Chacko and John
      <sup>
       <xref rid="bibr105-1759720X20947296" ref-type="bibr">105</xref>
      </sup>
     </td>
     <td rowspan="1" colspan="1">✓ Chong 
      <italic>et al</italic>.
      <sup>
       <xref rid="bibr106-1759720X20947296" ref-type="bibr">106</xref>
      </sup>
     </td>
     <td rowspan="1" colspan="1">✓ Review (
      <italic>n</italic> = 45): viremia clearance in 73% of patients
      <sup>
       <xref rid="bibr107-1759720X20947296" ref-type="bibr">107</xref>
      </sup>
     </td>
    </tr>
    <tr>
     <td rowspan="1" colspan="1"/>
     <td rowspan="1" colspan="1">BK virus</td>
     <td rowspan="1" colspan="1"/>
     <td rowspan="1" colspan="1"/>
     <td rowspan="1" colspan="1">✓ Phase II RCT (
      <italic>n</italic> = 46): viremia decreased, no improvement of renal function
      <sup>
       <xref rid="bibr108-1759720X20947296" ref-type="bibr">108</xref>
      </sup>
     </td>
    </tr>
    <tr>
     <td rowspan="1" colspan="1"/>
     <td rowspan="1" colspan="1">RSV</td>
     <td rowspan="1" colspan="1">✓ Dunn 
      <italic>et al</italic>.
      <sup>
       <xref rid="bibr109-1759720X20947296" ref-type="bibr">109</xref>
      </sup>
     </td>
     <td rowspan="1" colspan="1">✓ Viral loads reduced
      <sup>
       <xref rid="bibr109-1759720X20947296" ref-type="bibr">109</xref>
      </sup>
     </td>
     <td rowspan="1" colspan="1"/>
    </tr>
    <tr>
     <td rowspan="1" colspan="1">
      <bold>Tofacitinib</bold>
     </td>
     <td rowspan="1" colspan="1">HTLV-1</td>
     <td rowspan="1" colspan="1"/>
     <td rowspan="1" colspan="1">✓ Prolong survival duration
      <sup>
       <xref rid="bibr110-1759720X20947296" ref-type="bibr">110</xref>
      </sup>
     </td>
     <td rowspan="1" colspan="1"/>
    </tr>
    <tr>
     <td rowspan="1" colspan="1">
      <bold>Thalidomide</bold>
     </td>
     <td rowspan="1" colspan="1">HHV-8</td>
     <td rowspan="1" colspan="1"/>
     <td rowspan="1" colspan="1"/>
     <td rowspan="1" colspan="1">✓ Phase II (
      <italic>n</italic> = 17): 35% partial response rate
      <sup>
       <xref rid="bibr111-1759720X20947296" ref-type="bibr">111</xref>
      </sup>
      <break/>✓ Phase II (
      <italic>n</italic> = 20): 40% partial responses and 10% stable disease
      <sup>
       <xref rid="bibr112-1759720X20947296" ref-type="bibr">112</xref>
      </sup>
     </td>
    </tr>
   </tbody>
  </table>
 </alternatives>
 <table-wrap-foot>
  <fn id="table-fn6-1759720X20947296">
   <p>AD, atopic dermatitis; CMV, cytomegalovirus; CsA, cyclosporine A; DENV, dengue virus; DMARDs, disease-modifying anti-rheumatic drugs; HAART, highly active antiretroviral therapy; Hb, hemoglobin; HBV, hepatitis B virus; HCQ, hydroxychloroquine; HCV, hepatitis C virus; HHV-8, human herpesvirus 8; HIV, human immunodeficiency virus; HSV, herpes simplex virus; HTLV-I, human T cell lymphotrophic virus-1; MERS-CoV, Middle East respiratory syndrome coronavirus; MMF, mycophenolate mofetil; PCT, porphyria cutanea tarda; RCT, randomized-controlled trial; RSV, respiratory syncytial virus; RNA, ribonucleic acid; SARS-CoV, severe acute respiratory syndrome coronavirus.</p>
  </fn>
 </table-wrap-foot>
</table-wrap>
